Approved indications
Striverdi Respimat is FDA-approved as a long-term, once-daily maintenance bronchodilator for adults with COPD, including chronic bronchitis and/or emphysema, to improve airflow and reduce breathing difficulty; it is not approved for asthma or for relief of sudden breathing problems.

Off-label uses
In practice, Striverdi Respimat is used almost exclusively for COPD, because LABA medicines without an inhaled corticosteroid are not recommended for asthma and there are no widely accepted, well-supported off-label uses.

Efficacy expectations
Many people notice easier breathing and less shortness of breath within the first few days, with full benefit typically seen over several weeks of daily use. Clinical studies show improved lung function (such as higher FEV1), better symptom control, and less need for rescue inhaler use compared with placebo, with effects lasting through the 24-hour dosing interval. Its overall bronchodilator effect is similar to other once-daily LABA inhalers; some patients may experience additional benefit when it is used together with other maintenance COPD medications such as long-acting muscarinic antagonists (LAMA) or inhaled corticosteroids in separate or combination inhalers.

Typical dosing and how to take it
The usual adult dose for COPD is two inhalations by mouth once daily using the Striverdi Respimat inhaler, for a total of 5 micrograms of olodaterol per day. The dose should be taken at the same time each day, with or without food, and should not be taken more than once in 24 hours. It is meant for regular, daily maintenance use, not for quick relief of sudden breathing problems.

Administration instructions
Use the Respimat device exactly as shown in the patient instructions: insert the cartridge, prepare (prime) the inhaler before first use, and turn, open, and press to release a slow-moving mist while breathing in steadily and deeply through the mouth. If the inhaler has not been used for several days, it may need to be primed again according to the device instructions. After inhaling, close the cap and store the device upright when possible.

Special dosing instructions
Striverdi Respimat is not recommended for children or adolescents under 18 years of age. Do not increase the number of inhalations beyond the prescribed two inhalations once daily, even if symptoms feel worse, and do not combine it with other long-acting beta2-agonist (LABA) inhalers.

Missed dose guidance
If you miss a dose, take it as soon as you remember on the same day, then take your next dose at the usual time the following day. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take extra inhalations to make up for a missed dose.

Overdose
In case of overdose or if someone accidentally takes more inhalations than prescribed, symptoms may include very fast or irregular heartbeat, chest pain, tremor, headache, nervousness, or weakness. Emergency medical care or advice from poison control should be sought immediately if overdose is suspected.

Common side effects
Common side effects (generally mild to moderate and occurring in a small percentage of users) include runny or stuffy nose, sore throat, cough, upper respiratory infection, bronchitis, dizziness, rash, joint or back pain, and sometimes nervousness or tremor. These effects often appear in the first days to weeks of treatment and may lessen as your body adjusts, but persistent or bothersome symptoms should be discussed with a healthcare professional.

Serious or rare adverse effects
Serious but less common reactions that need urgent medical attention include sudden worsening of breathing right after using the inhaler (paradoxical bronchospasm), severe allergic reactions (such as swelling of the face, lips, tongue or throat, trouble breathing, or widespread rash), chest pain, very fast or irregular heartbeat, fainting, or signs of very low potassium (muscle weakness, cramps, or irregular heartbeat). Overuse or overdose of this LABA medicine can lead to significant rapid heartbeat, high blood pressure or low blood pressure, chest pain, tremor, or changes in blood potassium or blood sugar.

Warnings and precautions
Striverdi Respimat should not be used for sudden breathing problems or as a rescue inhaler. It is not approved for asthma and LABA medicines without an inhaled corticosteroid have been associated with an increased risk of asthma-related death. Use with caution in people with heart disease, high blood pressure, seizure disorders, thyroid problems, or those who are unusually sensitive to sympathomimetic ("adrenergic") drugs. Safety and effectiveness have not been established in children or adolescents under 18 years of age. In pregnancy or breastfeeding, use is generally considered only if the expected benefit justifies potential risks, since human data are limited. No specific dose adjustments are usually required for kidney or mild-to-moderate liver problems, but such patients should be monitored more closely.

Relative safety compared with similar drugs
When used at the recommended dose in adults with COPD, the overall safety profile of Striverdi Respimat is comparable to other LABA inhalers, with cardiovascular and paradoxical bronchospasm risks considered class effects. As with all LABAs, minimizing unnecessary high doses and avoiding use in asthma without an inhaled steroid are key safety measures.

Side-effect reporting and safety updates
Patients and caregivers in the United States can report side effects to the FDA through the MedWatch program (online or by phone) or by contacting the manufacturer. Up-to-date safety information, including new warnings or recalls, can be found via the FDA’s website or other official drug safety communication channels.

Drug and supplement interactions
Using Striverdi Respimat with other long-acting beta2-agonists (LABAs) or high doses of short-acting beta2-agonists may increase the risk of side effects such as fast heartbeat, tremor, or low potassium and is generally not recommended. Medicines that affect heart rhythm (including some antiarrhythmics and certain antibiotics or antidepressants), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and other adrenergic drugs can increase cardiovascular risks when combined with this inhaler. Diuretics (water pills), xanthine derivatives (such as theophylline), and systemic corticosteroids may enhance low blood potassium when used with LABAs. Beta-blockers (especially nonselective ones like propranolol) can reduce the effect of olodaterol and may provoke bronchospasm in people with COPD; they should be used cautiously and only when clearly needed.

Food, alcohol, and procedures
There are no specific food restrictions with Striverdi Respimat. Moderate alcohol use has no well-defined direct interaction but may increase the chance of feeling dizzy or lightheaded in some people. Like other beta-agonists, olodaterol may increase the risk of heart rhythm disturbances during certain types of general anesthesia, especially with halogenated hydrocarbons, so anesthesiology teams should be informed that the patient uses this inhaler.

Conditions requiring extra caution
Particular care is needed in people with coronary artery disease, heart rhythm problems, high blood pressure, convulsive disorders, overactive thyroid, or those unusually sensitive to adrenergic drugs. It should not be used in patients with asthma without the protection of an inhaled corticosteroid and is not indicated in children or adolescents. If COPD suddenly worsens, if rescue inhaler use increases, or if there is no improvement with regular use, the treatment plan should be reassessed rather than simply increasing the dose of Striverdi.

Monitoring
Clinicians typically monitor symptoms, rescue inhaler use, and lung function (such as spirometry) to assess effectiveness. Heart rate and blood pressure may be checked periodically, particularly in patients with cardiovascular disease, and blood potassium or blood sugar may be monitored in those at higher risk of abnormalities.

Q: Is Striverdi Respimat a rescue inhaler?
A: No, Striverdi Respimat is a maintenance inhaler for daily use in COPD and does not work quickly enough to treat sudden breathing attacks; a separate fast-acting rescue inhaler is still needed.

Q: How long does it take for Striverdi Respimat to start working?
A: Some people feel breathing improvement within the first day, but the full benefit usually develops over several days to a few weeks of taking the medicine every day.

Q: Can Striverdi Respimat be used for asthma?
A: It is not approved for asthma and LABA medicines like olodaterol should not be used alone in asthma because of an increased risk of serious asthma-related problems; it is intended only for adults with COPD.

Q: Can I use Striverdi Respimat with other COPD inhalers?
A: It is often used together with other types of COPD medicines, such as long-acting muscarinic antagonists (LAMA) or inhaled corticosteroids, but it should not be combined with another LABA; the full inhaler regimen should be coordinated by a healthcare professional.

Q: What should I do if I keep feeling short of breath while on Striverdi Respimat?
A: Use your prescribed rescue inhaler for quick relief and contact your healthcare team promptly, because persistent or worsening breathlessness may mean your COPD treatment plan needs to be adjusted.

Q: How long does one Striverdi Respimat inhaler last?
A: Each inhaler is designed to provide a set number of doses (usually 30 days at the standard 2 inhalations once daily), and it should be discarded when the dose indicator reaches zero or 3 months after first use, whichever comes first.

Storage

• Store at room temperature, generally 68°F to 77°F (20°C to 25°C), and keep the inhaler away from heat, open flame, and freezing.
• Keep the cap closed when not in use and store the inhaler and cartridge together, out of the reach of children and pets.
• Do not use the inhaler after the dose indicator reaches zero or more than 3 months after first use, even if it still sprays.

Disposal

• When the inhaler is empty or past its discard date, throw it away in household trash in a way that children and pets cannot reach it.
• Do not puncture or burn the inhaler, even if it appears empty.
• If local programs for medicine take-back are available, you may use them for safer disposal of used or expired inhalers.